Observational analysis shows improved motor function in Parkinson's disease with resynchronized microglial activity, highlighting P2X7 receptorial involvement.
Neuroinflammation is a key factor in Parkinson's disease (PD) pathogenesis. However, the regional heterogeneity of biomarkers related to inflammation in PD is less well defined. We developed [18F]GSK PET imaging to quantify neuroinflammation via the P2X7 receptor (P2X7R) in A53T PD male mice and wild-type (WT) male mice. Montelukast (MK) was administered to mice, and weekly behavior tests confirmed MK's efficacy. [18F]L-DOPA/[18F]GSK PET, motor testing, autoradiography, and immunofluorescence were performed after MK treatments. MK improved motor function and reduced the brain uptake of [18F]GSK, indicating resynchronization of regional microglial activity. The whole brain uptake of [18F]GSK was correlated with motor functional restoration, while [18F]L-DOPA PET was not. Overall, our study indicated that brain mapping of [18F]GSK PET is beneficial for exploring P2X7R-related neuroinflammation, which is correspondent to motor function in PD. Brain PET-MRI imaging shows higher [18F]GSK uptake across multiple regions in A53T compared to WT mice. Correlation analyses reveal that resynchronization of microglia in Parkinson's disease is associated with motor function restoration.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: